In another study, EGFR-TKIs (erlotinib or gefitinib) plus statins (atorvastatin or simvastatin) prolonged PFS in patients with advanced NSCLC harboring KRAS mutations23. Here, KRAS is linked to non-small cell lung carcinoma.